Thor Medical ASAFRA:8NN +0.14%26 Pretax Margin % is -7,579.41% as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Thor Medical ASA ranks worse than 93.42% on this metric.
The historical rank and industry rank for Thor Medical ASA's Pretax Margin % or its related term are showing as below:
FRA:8NN'
s Pretax Margin % Range Over the Past 10 Years
Min: -97163.25 Med: -74895.22 Max: -12460
Current: -12460
FRA:8NN's Pretax Margin % is ranked worse than 93.42% of 942
companies
in the Biotechnology industry
Industry Median: -90.5
vs FRA:8NN: -12460.00
Thor Medical ASA (FRA:8NN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thor Medical ASA Pretax Margin % Related Terms
Thor Medical ASA Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8NN vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Thor Medical ASA's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thor Medical ASA (FRA:8NN) has a Pretax Margin % of -7,579.41% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Thor Medical ASA and its competitors. According to the industry distribution chart, Thor Medical ASA ranks #880 out of 942 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Thor Medical ASA's Pretax Margin % too high?
Thor Medical ASA's current Pretax Margin % is -7,579.41%. Based on the distribution chart, Thor Medical ASA ranks #880 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Thor Medical ASA has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #880 out of 942 companies for Pretax Margin %. This places Thor Medical ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current Pretax Margin % is -7,579.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current Pretax Margin % of -7,579.41%. The current Pretax Margin % is -7,579.41%. Thor Medical ASA's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current Pretax Margin % is -7,579.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
26GF Score
Get the complete analysis for FRA:8NN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8NN has been successfully added to your 
